SCHEMBL3000441

SCHEMBL3000441

CCCCOC(=O)c1cccc(CCN(C)C(=O)OC(C)(C)C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.46
CYP4A11 Q02928 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2C19 P33261 2/20 0.42
NPC1 O15118 1/20 0.42
CYP2C9 P11712 1/20 0.42
HPGD P15428 1/20 0.42
RAB9A P51151 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ESR1 P03372 3/20 0.41
ALDH1A1 P00352 2/20 0.41
SLC7A5 Q01650 1/20 0.41
CYP2D6 P10635 2/20 0.40
LMNA P02545 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
NR1H2 P55055 1/20 0.40
RNASEL Q05823 1/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012969 0.93 ALDH1A1 (0.47) CYP4F2CYP4A11SMN1; SMN2RAB9AALDH1A1
SCHEMBL31239046 0.93 ALDH1A1 (0.47) CYP4F2CYP4A11SMN1; SMN2RAB9AALDH1A1
SCHEMBL3005511 0.89 CYP4F2 (0.43) CYP4F2CYP4A11SMN1; SMN2RAB9AALDH1A1
SCHEMBL3006290 0.84 CYP4F2 (0.57) CYP4F2CYP4A11SMN1; SMN2HPGDRAB9A
SCHEMBL15800476 0.84 CYP4F2 (0.54) CYP4F2CYP4A11SMN1; SMN2CYP1A2CYP2C19
SCHEMBL3010698 0.81 MRGPRX4 (0.45) SMN1; SMN2RAB9AL3MBTL1SLC7A5TP53
SCHEMBL29580473 0.81 MRGPRX4 (0.45) SMN1; SMN2RAB9AL3MBTL1SLC7A5TP53
SCHEMBL15344564 0.80 CYP4F2 (0.61) CYP4F2CYP4A11SMN1; SMN2CYP1A2CYP2C19
SCHEMBL1067976 0.78 TDP1 (0.55) SMN1; SMN2CYP1A2CYP2C19L3MBTL1ALDH1A1
SCHEMBL3401255 0.77 CYP2D6 (0.48) CYP4F2CYP4A11SMN1; SMN2CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250195462-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF MILESTONE PHARMACEUTICALS INC (CA) 2025-06-19 US disclosed
US-20240366552-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF MILESTONE PHARMACEUTICALS INC (CA) 2024-11-07 US disclosed
US-20240115543-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF MILESTONE PHARMACEUTICALS INC (CA) 2024-04-11 US disclosed
US-20230255923-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF MILESTONE PHARMACEUTICALS INC (CA) 2023-08-17 US disclosed
US-20220142963-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF MILESTONE PHARMACEUTICALS INC (CA) 2022-05-12 US disclosed
US-20210315855-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF MILESTONE PHARMACEUTICALS INC (CA) 2021-10-14 US disclosed
US-20210059972-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF MILESTONE PHARMACEUTICALS INC (CA) 2021-03-04 US disclosed
US-20200230097-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF MILESTONE PHARMACEUTICALS INC (CA) 2020-07-23 US disclosed
US-20190142781-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF MILESTONE PHARMACEUTICALS INC (CA) 2019-05-16 US disclosed
US-20180280339-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF MILESTONE PHARMACEUTICALS INC (CA) 2018-10-04 US disclosed
US-20160374982-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ACQUIOM AGENCY SERVICES, LLC 2016-12-29 US disclosed
US-9463179-B2 Short acting phenylalkylamine calcium channel blockers and uses thereof MILESTONE PHARMACEUTICALS INC. (CA) 2016-10-11 US disclosed
US-20160074354-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ACQUIOM AGENCY SERVICES, LLC 2016-03-17 US disclosed
US-9227918-B2 Short acting phenylalkylamine calcium channel blockers and uses thereof MILESTONE PHARMACEUTICALS (CA) 2016-01-05 US disclosed
US-20140296335-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ACQUIOM AGENCY SERVICES, LLC 2014-10-02 US disclosed
EP-2170050-B1 Short acting phenylalkylamine calcium channel blockers and uses thereof MILESTONE PHARMACEUTICALS INC (CA) 2014-06-18 EP disclosed
US-20100190852-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF MILESTONE PHARMACEUTICALS INC. (CA) 2010-07-29 US disclosed
CN-101754678-A Short-acting phenalkylamine calcium channel blockers and uses thereof MILESTONE PHARMACEUTICALS INC 2010-06-23 CN disclosed
EP-2170050-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF Milestone Pharmaceuticals Inc. (CA) 2010-04-07 EP disclosed
WO-2008156820-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF MILESTONE PHARMACEUTICALS INC. (CA) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200230097-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ORAI1, ATP2A1, RYR2 CYP4F2 3383/4885CYP4A11 2712/4885SMN1; SMN2 838/4885
US-20240115543-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ORAI1, ATP2A1, RYR2 CYP4F2 3383/4885CYP4A11 2712/4885SMN1; SMN2 838/4885
US-20220142963-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ORAI1, ATP2A1, RYR2 CYP4F2 3383/4885CYP4A11 2712/4885SMN1; SMN2 838/4885
US-20190142781-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ORAI1, ATP2A1, RYR2 CYP4F2 3383/4885CYP4A11 2712/4885SMN1; SMN2 838/4885
US-20230255923-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ORAI1, ATP2A1, RYR2 CYP4F2 3383/4885CYP4A11 2712/4885SMN1; SMN2 838/4885
US-20160374982-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ORAI1, ATP2A1, RYR2 CYP4F2 3383/4885CYP4A11 2712/4885SMN1; SMN2 838/4885
US-20240366552-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ORAI1, ATP2A1, RYR2 CYP4F2 3383/4885CYP4A11 2712/4885SMN1; SMN2 838/4885
US-20210315855-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ORAI1, ATP2A1, RYR2 CYP4F2 3383/4885CYP4A11 2712/4885SMN1; SMN2 838/4885
US-20210059972-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ORAI1, ATP2A1, RYR2 CYP4F2 3383/4885CYP4A11 2712/4885SMN1; SMN2 838/4885
US-20140296335-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ORAI1, ATP2A1, RYR2 CYP4F2 3383/4885CYP4A11 2712/4885SMN1; SMN2 838/4885
US-20180280339-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ORAI1, ATP2A1, RYR2 CYP4F2 3383/4885CYP4A11 2712/4885SMN1; SMN2 838/4885
US-20160074354-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ORAI1, ATP2A1, RYR2 CYP4F2 3383/4885CYP4A11 2712/4885SMN1; SMN2 838/4885
US-20100190852-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ORAI1, ATP2A1, RYR2 CYP4F2 3383/4885CYP4A11 2712/4885SMN1; SMN2 838/4885
US-20250195462-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ORAI1, ATP2A1, RYR2 CYP4F2 3383/4885CYP4A11 2712/4885SMN1; SMN2 838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.